Total syntheses of (+)- and (-)-cacospongionolide B, cacospongionolide E, and related analogues. Preliminary study of structural features acquired for phospholipase A2 inhibition

Journal of Organic Chemistry

Volumn 69, Issue 17, 2004, Pages 5712-5719

  Cheung, Atwood K ^a   Murelli, Ryan ^a   Snapper, Marc L ^a  

^a BOSTON COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYMES; METABOLITES;

ENANTIOSPECIFIC INTERACTIONS;

SYNTHESIS (CHEMICAL);

BEE VENOM; BUTENOLIDE; CACOSPONGIONOLIDE B; CACOSPONGIONOLIDE E; GAMMA HYDROXYBUTENOLIDE; MANOALIDE; NATURAL PRODUCT; PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASYMMETRIC SYNTHESIS; CATALYSIS; COVALENT BOND; ENANTIOMER; ENZYME ACTIVE SITE; ENZYME INHIBITION; LIPID BILAYER; MOLECULAR INTERACTION; RING CLOSING METATHESIS; SPONGE (PORIFERA); STRUCTURE ANALYSIS;

4-BUTYROLACTONE; ANIMALS; ENZYME INHIBITORS; MOLECULAR STRUCTURE; PHOSPHOLIPASES A; PORIFERA; PYRANS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4043093297     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo049285e     Document Type: Article

References (152)

1. (a) De Rosa, S.; Crispino, A.; De Giulio, A.; Iodice, C.; Amodeo, P.; Tancredi, T. J. Nat. Prod. 1999, 62, 1316-1318.
2. (b) De Rosa, S.; Crispino, A.; De Giulio, A.; Iodice, C.; Benrezzouk, R.; Terencio, M. C.; Ferrándiz, M. L.; Alcaraz, M. J.; Paya, M. J. Nat. Prod. 1998,61, 931-935.
3. (c) De Rosa, S.; Puliti, R.; Crispino, A.; De Giulio, A.; De Sena, C.; Iodice, C.; Mattia, C. A. Tetrahedron 1995, 57, 10731-10736.
4. De Rosa, S.; Crispino, A.; De Giulio, A.; Iodice, C.; Benrezzouk, R.; Terencio, M. C.; Ferrándiz, M. L.; Alcaraz, M. J.; Payá, M. J. Nat. Prod. 1998, 67, 931-935.
5. (a) De Rosa, S.; Crispino, A.; De Giulio, A.; Iodice, C.; Pronzato, R.; Zavodnik, N. J. Nat. Prod. 1905, 58, 1776-1780.
6. (b) Garcia Pastor, P.; De Rosa, S.; De Giulio, A.; Payá, M.; Alcaraz, M. J. Brit. J. Pharm. 1999, 726, 301-311.
7. (c) De Rosa, M.; Giordano, S.; Scettri, A.; Sodano, G.; Soriente, A.; García Pastor, P.; Alcaraz, M. J.; Payá, M. J. Med. Chem. 1998, 41, 1, 3232-3238.
8. Cacospongionolide B is also reported to suppress expression of inflammatory enzymes by inhibiting nuclear factor-κB activation. Posadas, I.; De Rosa, S.; Terencio, M. C.; Payá, M.; Alcaraz, M. J. Brit. J. Pharm. 2003, 138, 1571-1579.
9. (a) De Suva, E. D.; Scheuer, P. J. Tetrahedron Lett. 1980, 21, 1611-1614.
10. (b) Glaser, K. B.; De Carvalho, S. M.; Jacobs, R. S.; Kernan, M. R.; Faulkner, D. J. Mol. Pharmocol. 1989, 36, 782-788.
11. (c) de Freitas, J. C.; Blankemeier, L. A.; Jacobs, R. S. Experientia 1984, 40, 864-865.
12. (d) Jacobs, R. S.; Culver, P.; Langdon, R.; O'Brien, T.; White, S. Tetrahedron 1985, 41, 981-984.
13. (e) Mayer, A. M. S.; Jacobs, R. S. Biomédical Importance of Marine Organism; Fautin, D. G., Ed.; California Academy of Sciences: San Francisco, 1988; pp 133-142.
14. (f) Mann, J. Nature 1992, 358, 540.
15. (a) Six, D. A.; Dennis, E. A. Biochim. Biophys. Acta 2000, 1488, 1-19.
16. (b) Tibes, U.; Friebe, W.-G. Exp. Opin. Invest. Drugs 1997, 6, 279-298.
17. (c) Gelb, M. H.; Jain, M. K.; Berg, O. G. FASEB J. 1994, 8, 916-924.
18. (d) Dennis, E. A. Drug. Dev. Res. 1987, 10, 205-220.
19. (e) Soriente, A.; De Rosa, M.; Scettri, A.; Sodano, G.; Terencio, M. C.; Payá, M.; Alcaraz, M. J. Curr. Med. Chem. 1999, 6, 415-431.
20. (a) Potts, B. C. M.; Faulkner, D. J.; Jacobs, R. S. J. Nat. Prod. 1992, 55, 1701-1717.
21. (b) Potts, B. C. M.; Faulkner, D. J.; De Carvalho, M. S.; Jacobs, R. S. J. Am. Chem. Soc. 1992, 114, 5093-5100.
22. For a preliminary report on the synthesis of cacospongionolide B, see Cheung, A. K.; Snapper, M. L. J. Am. Chem. Soc. 2002, 124, 11584-11585.
23. For alternative approaches to cacospongionolide B, see De Rosa, M.; Soriente, A.; Giudo, S.; Scettri, A. Tetrahedron 2000, 56, 2095-2102
24. and references therein. For the total synthesis of cacospongionolide F, see Darntew, D.; Forsyth, C. J. Org. Lett. 2003, 5, 991-994.
25. (a) Casaubon, R. L.; Snapper, M. L. Bioorg. Med. Chem. Lett. 2001, 11, 133-136.
26. (b) Radeke, H. S.; Digits, C. A.; Casaubon, R. L.; Snapper, M. L. Chem. Biol. 1999, 6, 639-647.
27. (c) Radeke, H. S.; Digits, C. A.; Bruner, S. D.; Snapper, M. L. J. Org. Chem. 1997, 62, 2823-2831.
28. (a) Ulmer, J. B.; Palade, G. E. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 6992-6996.
29. (b) Sampath, D.; Varki, A.; Freeze, H. H. J. Biol. Chem. 1992, 267, 4440-4455.
30. (a) Jones, K. Am. Biotechnol. Lab. 1990, 8, 26-30.
31. (b) Fretz, H.; Albers, M. W.; Galat, A.; Standaert, R. F.; Lane, W. S.; Burakoff, S. J.; Bierer, B. E.; Schreiber, S. L. J. Am. Chem. Soc. 1991, 113, 1409-1411.
32. Radeke, H. S.; Snapper, M. L. Bioorg. Med. Chem. 1998, 6, 1227-1232.
33. Soriente, A.; De Rosa, M.; Scettri, A.; Sodano, G.; Terencio, M. C.; Paya, M.; Alcaraz, M. J. Curr. Med. Chem. 1999, 6, 415-431.
34. For a review on the generating quaternary carbon centers, see Martin, S. F. Tetrahedron 1980, 36, 419-460.
35. (a) Stork, G.; Rosen, P.; Goldman, N. L. J. Am. Chem. Soc. 1961, 83, 2965-2966.
36. (b) Stork, G.; Rosen, P.; Goldman, N. L.; Coombs, R. V.; Tsuji, J. J. Am. Chem. Soc. 1965, 87, 275-286.
37. (a) Swaminathan, S.; Newman, M. S. Tetrahedron 1958, 2, 88-99.
38. (b) Eder, U.; Sauer, G.; Wiechert, R. Angew. Chem., Int. Ed. Engl. 1971, 10, 496-497.
39. Racherla, U. S.; Liao, Y.; Brown, H. C. J. Org. Chem. 1992, 57, 6614-6617.
40. (a) Denmark, S. E.; Coe, D. M.; Pratt, N. E.; Griedel, B. D. J. Org. Chem. 1994, 59, 6161-6163.
41. (b) Keck, G. E.; Geraci, L. S. Tetrahedron Lett. 1993, 34, 7827-7828.
42. (c) Nakamura, K.; Nakamura, H.; Yamamoto, Y. J. Org. Chem. 1999, 64, 2614-2615.
43. (d) Nakajima, M.; Saito, M.; Shiro, M.; Hashimoto, S. J. Am. Chem. Soc. 1998, 120, 6419-6420.
44. (e) Yamada, K. Tozawa, T.; Nishida, M.; Mukaiyama, T. Bull. Chem. Soc. Jpn. 1997, 70, 2301-2308.
45. (f) Sugimoto, K.; Aoyagi, S.; Kibayashi, C. J. Org. Chem. 1997, 62, 2322-2323.
46. (g) Bedeschi, P.; Casolari, S.; Costa, A. L.; Tagliavini, E.; Umani-Ronchi, A. Tetrahedron Lett. 1995, 36, 7897-7900.
47. (h) Yu, C.-M.; Choi, H.-S.; Jung, W.-H.; Lee, S.-S. Tetrahedron Lett. 1996,37, 7095-7098.
48. (i) Held, C.; Fröhlich, R.; Metz, P. Angew. Chem., Int. Ed. 2001, 40, 1058-1060.
49. (a) Sharma, G. V. M.; Krishnudu, K. Tetrahedron Lett. 1995, 36, 2661-2664.
50. (b) Mandal, P. K.; Maiti, G.; Roy, S. C. J. Org. Chem. 1998, 63, 2829-2834.
51. (c) Rochet, P.; Vatele, J.-M.; Gore, J. Synthesis 1994, 8, 795-799.
52. (d) Frissen, A. E.; Marcelis, A. T.; Buurman, D. G.; Pollmann, C. A. M.; Van der Plas, H. C. Tetrahedron 1989, 45, 5611-5620.
53. (a) Kim, S.-H.; Bowden, N.; Grubbs, R. H. J. Am. Chem. Soc. 1994, 116, 10801-10802.
54. (b) Kinoshita, A.; Mori, M. Synlett 1994, 1020-1022.
55. (c) Kinoshita, A.; Mori, M. J. Org. Chem. 1996, 61, 8356-8357.
56. (d) Kinoshita, A.; Sakakibara, N.; Mori, M. J. Am. Chem. Soc. 1997, 119, 12388-12389.
57. (e) Mori, M.; Sakakibara, N.; Kinoshita, A. J. Org. Chem. 1998, 63, 6082-6083. For recent reviews, see
58. For recent reviews see (f) Poulsen, C. S.; Madsen, R. Synthesis 2003, 1-18.
59. (g) Mori, M. Top. Organomet. Chem. 1998, 1, 133-154.
60. For other examples of enyne metatheses see (h) Katz, T. J.; Sivavec, T. M. J. Am. Chem. Soc. 1985, 107, 737-738.
61. (i) Trost, B. M.; Tanoury, G. J. J. Am. Chem. Soc. 1988, 110, 1636-1638.
62. (j) Watanuki, S.; Ochifuji, N.; Mori, M. Organometallics 1994, 13, 4129-4130.
63. (k) Chatani, N.; Morimoto, T.; Muto, T.; Murai, S. J. Am. Chem. Soc. 1994, 116, 6049-6050.
64. (l) Aubert, C.; Buisine, O.; Malacria, M. Chem. Rev. 2002, 102, 813-834.
65. (a) White, J. D.; Hanselmann, R.; Wardrop, D. J. J. Am. Chem. Soc. 1999, 121, 1106-1107.
66. (b) Nicolaou, K. C.; Bertinato, P.; Piscapio, A. D.; Chakraborty, T. K.; Minowa, N. J. J. Chem. Soc. Chem. Commun. 1993, 619-622.
67. (c) Ragan, J. A.; Nakatsuka, M.; Smith, D. B.; Uehling, D. E.; Schreiber, S. L. J. Org. Chem. 1989, 54, 4267-4268.
68. (d) Negishi, E.; Takahashi, T. Aldirchim. Acta 1985, 2 (18), 31-47.
69. (e) Bertelo, C. A.; Schwartz, J. J. Am. Chem. Soc. 1976, 98, 262-264.
70. (f) Hart, D. W.; Schwartz, J. J. Am. Chem. Soc. 1974, 96, 8115-8116.
71. (g) Schwartz, J.; Labinger, J. A. Angew. Chem., Int. Ed. Engl. 1976, 15, 333-339. For a recent review, see
72. For a recent review see (h) Wipf, P.; Jahn, H. Tetrahedron 1996, 52, 12853-12910.
73. (i) Wipf, P.; Kendall, C. Chem.-Eur. J. 2002, 8, 1778-1784.
74. (j) Wipf, P.; Takahashi, H.; Nian, Z. Pure Appl. Chem. 1998, 70, 1077-1082.
75. (k) Wipf, P.; Xu, W.; Takahashi, H.; Jahn, H.; Coish, P. D. G. Pure Appl. Chem. 1997, 69, 639-644.
76. (a) Chambers, M. S.; Thomas, E. J. J. Chem. Soc., Perkin Trans. 1 1997, 4, 417-431.
77. (b) Kranz, M.; Kessler, H. Tetrahedron Lett. 1996, 37, 5359-5362.
78. (c) Amoo, V. E.; Bernardo, De S.; Weigele, M. Tetrahedron Lett. 1988, 29, 2401-2404.
79. (a) Theodorakis, E. A.; Drouet, K. E. J. Am. Chem. Soc. 1999, 121, 456-457.
80. (b) Tse, B. J. Am. Chem. Soc. 1996, 118, 7094-7100.
81. (c) Li, J.; Lan, J.; Liu, Z.; Li, Y.; Li, Y. Tetrahedron: Asymmetry 1996, 7, 2851-2862.
82. (a) Hagiwara, H.; Uda, H. J. Org. Chem. 1988, 53, 2308-2311.
83. (b) Hajos, Z. G.; Parrish, D. R. J. Org. Chem. 1974, 12, 1615-1621.
84. (c) Eder, U.; Sauer, G.; Wiechert, R. Angew. Chem., Int. Ed. Engl. 1971, 10, 496-497.
85. (d) Danishefsky, S.; Cain, P. J. Am. Chem. Soc. 1976, 98, 4975-4983.
86. (e) Hiroi, K.; Yamada, S. I. Chem. Pharm. Bull. 1975, 23, 1103-1109.
87. (f) Brown, K. L.; Damm, L.; Dunitz, J. D.; Eschenmoser, A.; Hobi, R.; Kratky, C. Helv. Chim. Acta 1978, 61, 3108-3135.
88. (g) Agami, C.; Meynier, F.; Puchot, C.; Guilhem, J.; Pascard, C. Tetrahedron 1984, 40, 1031-1038.
89. (h) Agami, C.; Puchot, C.; Sevestre, H. Tetrahedron Lett. 1986, 27, 1501-1504.
90. (i) Puchot, C.; Samuel, O.; Dunach, E.; Zhao, S.; Agami, C.; Kagan, H. B. J. Am. Chem. Soc. 1986, 108, 2353-2357.
91. (j) Agami, C.; Puchot, C. J. Mol. Catal. 1986,38, 341-343.
92. (k) Agami, C. Bull. Soc. Chim. Fr. 1987, 3, 499-507.
93. (l) Hoang, L.; Bahnmanyar, S.; Houk, K. N.; List, B. J. Am. Chem. Soc. 2003, 125, 16-17.
94. Ciceri, P.; Demnitz, F. W. J. Tetrahedron 1997, 38, 389-390.
95. For related alkylations, see (a) Ruggeri, R. B.; Hansen, M. M.; Heathcock, C. H. J. Am. Chem. Soc. 1988, 110, 8734-8736.
96. (b) Larsen, S. D.; Monti, S. A. J. Am. Chem. Soc. 1977, 99, 8015-8020.
97. (c) Corey, E. J.; Hartmann, R.; Vatakencherry, P. A. 1962, 84, 2611-2614.
98. (a) House, H. O.; Czuba, L. J.; Gall, M.; Olmstead, H. D. J. Org. Chem. 1969, 34, 2324-2336.
99. (b) Stork, G.; Hudrlik, P. F. J. Am. Chem. Soc. 1968, 90, 4462-4464.
100. (c) Stork, G.; Hudrlik, P. F. J. Am. Chem. Soc. 1968, 90, 4464-4465.
101. (d) Snitman, D. L.; Tsai, M.-Y.; Watt, D. S.; Edwards, C. L.; Stotter, P. L. J. Org. Chem. 1979, 44, 2838-2842.
102. (e) Smith, A. B., III; Mewshaw, R. J. Org. Chem. 1984, 49, 3685-3689.
103. Smith and Mewshaw observed no alkylation of similar lithium enolate with irans-1-iodo-3-pentene: Smith, A. B., III; Mewshaw, R. J. Org. Chem. 1984, 49, 3685-3689.
104. Morita, Y.; Suzuki, M.; Noyori, R. J. Org. Chem. 1989, 54, 1785-1787.
105. Posner, G. H.; Lentz, C. M. J. Am. Chem. Soc. 1979, 101, 934-946.
106. Rathke, M. W.; Lindert, A. Synthetic Commun. 1978, 8, 9-14.
107. Evans, D. A.; Nelson, J. V.; Vogel, E.; Taber, T. R. J. Am. Chem. Soc. 1981, 103, 3099-3111.
108. Yachi, K.; Shinokubo, H.; Oshima, K J. Am. Chem. Soc. 1999, 121, 9465-9466.
109. Mukaiyama, T.; Banno, K.; Narasaka, K. J. Am. Chem. Soc. 1974, 96 (6), 7503-7509.
110. For related Michael reactions, see (a) Stork, G.; Ganem, B. J. Am. Chem. Soc. 1973, 95, 6152-6153.
111. (b) Marshall, J. A.; Fanta, W. I. J. Org. Chem. 1964, 29, 2501-2505.
112. (c) Boeckman, R. K, Jr. J. Am. Chem. Soc. 1973, 95, 6867-6869.
113. (d) Boeckman, R. K, Jr. J. Am. Chem. Soc. 1974, 96, 6179-6181.
114. (e) Stork, G.; Singh, J. J. Am. Chem. Soc. 1974, 96, 6181-6182.
115. (a) Piscopio, A. D.; Minowa, N.; Chakraborty, T. K.; Kiode, K.; Bertinato, P.; Nicolaou, K. C. J. Chem. Commun. 1993, 617-618.
116. (b) Nahm, S.; Weinreb, S. M. Tetrahedron Lett. 1981, 39, 3815-3818.
117. For examples of related transformations, see (a) Stork, G.; Ganem, B. J. Am. Chem. Soc. 1973, 95, 6152-6153.
118. (b) Stork, G.; Singh, J. J. Am. Chem. Soc. 1974, 96, 6181-6182.
119. (c) Boeckman, R. K., Jr. J. Am. Chem. Soc. 1973, 95, 6867-6869.
120. (d) Boeckman, R. K., Jr. J. Am. Chem. Soc. 1974, 96, 6179-6181.
121. 1H NMR (i.e., <5%).
122. For a related example, see Winkler, J. D.; Rouse, M. B.; Greaney, M. F.; Harrison, S. J.; Jeon, Y. T. J. Am. Chem. Soc. 2002, 124, 9726-9728.
123. Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Org. Lett. 1999, 1, 953-956.
124. (a) Bruner, S. D.; Radeke, H. S.; Tallarico, J. A.; Snapper, M. L. J. Org. Chem. 1995, 60, 1114-1115.
125. (b) Almstead, J.-I. K.; Demuth, T. P., Jr.; Ledoussal, B. Tetrahedron: Asymmetry 1998, 9, 3179-3183.
126. (c) Markó, I. E.; Wiaux, M.; Warriner, S. M.; Giles, P. R.; Eustace, P.; Dean, D.; Bailey, M. Tetrahedron Lett. 1999, 40, 5629-5632.
127. (d) Ling, T.; Xiang, A. X.; Theodorakis, E. A. Angew. Chem., Int. Ed. Engl. 1999, 38, 3089-3091.
128. (e) Kende, A. S.; Rustenhoven, J. J.; Zimmermann, K. Tetrahedron Lett. 2000, 41, 843-846.
129. For recent reviews on catalytic asymmetric hydrogenation, see (a) Noyori, R. Acta Chem. Scared 1996, 50, 380-390.
130. (b) Nugent, W. A.; RajanBabu, T. V.; Burk, M. J. Science 1993, 259, 479-483.
131. (c) Ratovelomanana-Vidal, V.; Genêt, J.-P. J. Organomet. Chem. 1998, 567, 163-171.
132. (d) Helmchen, G.; Pfaltz, A. Acc. Chem. Res. 2000, 33, 336-345.
133. (e) Noyori, R.; Takaya, H. Acc. Chem. Res. 1990, 23, 345-350.
134. Otha, T.; Ikegami, H.; Miyake, T.; Takaya, H. J. Organomet. Chem. 1995, 502, 169-176.
135. Higher conversions gave significant amounts of pyran-olefin reduction that can be removed at a later stage by RP-HPLC.
136. Kernan, M. R.; Faulkner, D. J. J. Org. Chem. 1988, 53, 2773-2776.
137. For other syntheses of γ-hydroxybutenolide rings, see (a) Boukouvalas, J.; Lachance, N. Synlett 1998, 31-32.
138. (b) Gerlach, K.; Hoffmann, H. M. R.; Wartchow, R. J. Chem. Soc., Perkin Trans. 1 1998, 3867-3872.
139. (c) Katsumura, S.; Hori, K.; Fujiwara, S.; Isoe, S. Tetrahedron Lett. 1985, 26, 4625-4628.
140. (d) Larcheveque, M.; Legueut, C.; Debal, A.; Lallemand, J. Y. Tetrahedron Lett. 1981, 22, 1595-1598.
141. De Rosa, S.; Crispino, A.; De Giulio, A.; Iodice, C.; Benrezzouk, R.; Terencio, M. C.; Ferrándiz, M. L.; Alcaraz, M. J.; Paya, M. J. Nat. Prod. 1998, 61, 931-935.
142. (a) Casaubon, R. L.; Snapper, M. L. Chem. Biol. 1999, 6, 639-647.
143. (b) Radeke, H. S.; Snapper, M. L. Bioorg. Med. Chem. 1998, 6, 1227-1232.
144. At higher conversions, lower yields of the desired compound are obtained due to reduction of the trisubstituted dihydropyran olefin.
145. Contaminated with starting material and over-reduced materials.
146. (a) Butcher, J. S.; Macmillan, J. G.; Heathcock, C. H. J. Org. Chem. 1976, 41, 2663-2669.
147. (b) Radeke, H. S.; Digits, C. A.; Bruner, S. D.; Snapper, M. L. J. Org. Chem. 1997, 62, 2823-2831.
148. 2-inhibitory assays involve live animals or radiolabeled phospholipids. For examples, see (a) Garcia Pastor, P.; De Rosa, S.; De Giulio, A.; Paya, M.; Alcaraz, M. J. Brit. J. Pharm. 1999, 126, 301-311.
149. (b) Potts, B. C. M.; Faulkner, D. J.; Jacobs, R. S. J. Nat. Prod. 1992, 55, 1701-1717.
150. 2 Assay Kit from Cayman Chemical, Ann Arbor, MI (Catalog 765001).
151. Glaser, K. B.; De Carvalho, S. M.; Jacobs, R. S.; Kernan, M. R.; Faulkner, D. J. Mol. Pharmocol. 1989, 36, 782-788 and ref 3c.
152. De Rosa, S.; Crispino, A.; De Giulio, A.; Iodice, C.; Benrezzouk, R.; Terencio, M. C.; Ferrándiz, M. L.; Alcaraz, M. J.; Payá, M. J. Nat. Prod. 1998, 61, 931-935.